EUDA Health (EUDA) announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. to form a joint venture. Guangdong Cell Biotech develops autologous cell treatments and tailored medicines for various disorders. This potential collaboration aims to leverage the complementary strengths of both companies to accelerate growth and innovation across the biotechnology and consumer health sectors. Discussions are focused on leveraging EUDA’s digital healthcare ecosystem as a platform to deliver cutting-edge regenerative therapies developed by Guangdong Cell Biotech to a broader audience in Southeast Asia. Guangdong Cell Biotech’s stem cell technology is expected to enrich EUDA’s healthcare services with innovative treatment options, enhancing the appeal and effectiveness of its digital platform. Guangdong Cell Biotech represents that it currently has 37 established stem cell and DNA medical treatment facilities in China and presence in Indonesia and Cambodia. A joint venture combining EUDA’s expertise in making holistic healthcare solutions accessible to everyone using its portfolio of products and advanced technologies, with Guangdong Cell Biotech’s leadership in stem cell treatment, will allow EUDA to enhance its market presence, improve product offerings, and deliver cutting-edge solutions to customers in Asia. Parties have not entered into a letter of intent or a legally binding agreement at this time. There is no guarantee that parties will form a joint venture or enter into a definitive written agreement to collaborate in the future.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EUDA:
Questions or Comments about the article? Write to editor@tipranks.com